KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Current Deferred Revenue (2016 - 2019)

NovoCure's Current Deferred Revenue history spans 5 years, with the latest figure at $19.6 million for Q4 2019.

  • On a quarterly basis, Current Deferred Revenue rose 4.32% to $19.6 million in Q4 2019 year-over-year; TTM through Dec 2019 was $19.6 million, a 4.32% increase, with the full-year FY2019 number at $19.6 million, up 4.32% from a year prior.
  • Current Deferred Revenue hit $19.6 million in Q4 2019 for NovoCure, up from $18.8 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for NVCR hit a ceiling of $19.6 million in Q4 2019 and a floor of $52000.0 in Q4 2015.
  • Historically, Current Deferred Revenue has averaged $9.1 million across 5 years, with a median of $5.0 million in 2017.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 4259.62% in 2016 and later increased 4.32% in 2019.
  • Tracing NVCR's Current Deferred Revenue over 5 years: stood at $52000.0 in 2015, then skyrocketed by 4259.62% to $2.3 million in 2016, then soared by 118.75% to $5.0 million in 2017, then skyrocketed by 278.48% to $18.8 million in 2018, then rose by 4.32% to $19.6 million in 2019.
  • Business Quant data shows Current Deferred Revenue for NVCR at $19.6 million in Q4 2019, $18.8 million in Q4 2018, and $5.0 million in Q4 2017.